Subjects who fail to return. For Subjects who fail to return payment will be made on a pro rata basis according to the payment plan providing that the Principal Investigator has made a reasonable effort to contact them. The basis for such payments will be the last visit for which evaluable data was collected. This also applies for Subjects who enter run-in, but are ineligible at the randomization visit. Sponsor reserves the right to reduce or withhold payment for Subjects entered into the Study in violation of the eligibility criteria or for Subjects for whom essential data (e.g. primary efficacy / safety data) is missing. Sponsor will cover reasonable travel and accommodation costs for a pre-agreed number of Study site staff in connection with Study related meetings arranged by the Sponsor upon submission of tickets / receipts.
Appears in 6 contracts
Samples: Clinical Trial Agreement, Clinical Investigation Agreement, Clinical Investigation Agreement
Subjects who fail to return. For Subjects who fail to return payment will be made on a pro rata basis according to the payment plan providing that the Principal Investigator has made a reasonable effort to contact them. The basis for such payments will be the last visit for which evaluable data was collected. This also applies for Subjects who enter run-in, but are ineligible at the randomization visit. Sponsor reserves the right to reduce or withhold payment for Subjects entered into the Study Investigation in violation of the eligibility criteria or for Subjects for whom essential data (e.g. primary efficacy / safety data) is missing. Sponsor will cover reasonable travel and accommodation costs for a pre-agreed number of Study Investigation site staff in connection with Study Investigation related meetings arranged by the Sponsor upon submission of tickets / receipts.
Appears in 2 contracts
Samples: Clinical Investigation Agreement, Clinical Investigation Agreement
Subjects who fail to return. For Subjects who fail to return payment will be made on a pro rata basis according to the payment plan providing that the Principal Investigator has made a reasonable effort to contact them. The basis for such payments will be the last visit for which evaluable data was collected. This also applies for Subjects who enter run-in, but are ineligible at the randomization visit. Sponsor reserves the right to reduce or withhold payment for Subjects entered into the Study in violation of the eligibility criteria or for Subjects for whom essential data (e.g. eg. primary efficacy / safety data) is missing. Sponsor will cover reasonable travel and accommodation costs for a pre-agreed number of Study site staff in connection with Study related meetings arranged by the Sponsor upon submission of tickets / receipts. Driving costs will be refunded in accordance with the Norwegian Government's Travel Allowance Scale (“Statens reiseregulativ”).
Appears in 1 contract
Samples: Clinical Study Agreement
Subjects who fail to return. For Subjects who fail to return payment will be made on a pro rata basis according to the payment plan providing that the Principal Investigator has made a reasonable effort to contact them. The basis for such payments will be the last visit for which evaluable data was collected. This also applies for Subjects who enter run-in, but are ineligible at the randomization visit. Sponsor reserves the right to reduce or withhold payment for Subjects entered into the Study in violation of the eligibility criteria or for Subjects for whom essential data (e.g. eg.e.g. primary efficacy / safety data) is missing. Sponsor will cover reasonable travel and accommodation costs for a pre-agreed number of Study site staff in connection with Study related meetings arranged by the Sponsor upon submission of tickets / receipts.
Appears in 1 contract
Samples: Clinical Study Agreement